Sou Hu Cai Jing·2025-08-25 07:47Group 1 - The core viewpoint of the report is that Nuo Cheng Jian Hua (688428.SH) is given a "buy" rating due to several positive developments in its product pipeline and market approvals [1] - The approval of Obinutuzumab for 1LCLL/SLL indications in China is expected to drive rapid market growth [1] - Tafasitamab has received NMPA approval, indicating potential for commercial growth [1] - The company has initiated two registration clinical studies for ICP-248, indicating a global acceleration in its development strategy [1] - Nuo Cheng Jian Hua continues to explore multiple indications in the autoimmune field, with several innovative oral therapies progressing in development [1] - The company has submitted an NDA for ICP-732 in China and received priority review, while its first ADC candidate, ICP-B794, has been granted IND approval domestically [1] Group 2 - The A-share market has seen trading volumes exceed 2 trillion yuan for eight consecutive days, indicating strong market activity [2] - Major brokerage firms are actively recruiting for autumn positions, highlighting a demand for talent in the industry [2]